Assenagon Asset Management S.A. Has $183.76 Million Stock Position in CVS Health Corporation $CVS

Assenagon Asset Management S.A. raised its position in CVS Health Corporation (NYSE:CVS) by 102.7% during the second quarter, HoldingsChannel.com reports. The firm owned 1,776,295 shares of the pharmacy operator’s stock after buying an additional 899,942 shares during the quarter. Assenagon Asset Management S.A.’s holdings in CVS Health were worth $183,758,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its holdings in CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after buying an additional 281 shares during the last quarter. Swiss RE Ltd. acquired a new stake in CVS Health in the fourth quarter valued at approximately $26,000. Mcguire Capital Advisors Inc. bought a new stake in CVS Health in the fourth quarter worth approximately $28,000. Sankala Group LLC acquired a new position in shares of CVS Health during the 4th quarter worth $28,000. Finally, Global Trust Asset Management LLC raised its holdings in shares of CVS Health by 344.8% during the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock valued at $28,000 after purchasing an additional 300 shares in the last quarter. 80.66% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at CVS Health

In related news, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at approximately $586,842,501.45. The trade was a 24.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 3,372,000 shares of company stock valued at $317,473,598 in the last 90 days. Insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CVS. TD Cowen lifted their price objective on shares of CVS Health from $105.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Barclays increased their target price on shares of CVS Health from $106.00 to $108.00 and gave the stock an “overweight” rating in a research report on Thursday. UBS Group boosted their price target on CVS Health from $122.00 to $126.00 and gave the stock a “buy” rating in a research report on Thursday. Cantor Fitzgerald upped their price target on CVS Health from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 7th. Finally, Mizuho increased their price objective on CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Monday, June 8th. Twenty-two analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus price target of $106.46.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. All three major segments—Aetna insurance, pharmacy services and health services—contributed to the result. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and increased operating cash-flow guidance to at least $11.5 billion. Improved medical-cost performance at Aetna, stronger drug revenue and a more profitable pharmacy mix supported the outlook. CVS Health reports strong second-quarter results and raises full-year guidance
• Positive Sentiment: CVS also expanded its weight-management strategy through a collaboration with Eli Lilly, offering additional access to Zepbound and other GLP-1 treatments through CVS Pharmacy and its digital care platform. The initiative could support pharmacy traffic and future growth. CVS Health enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: The improving Aetna Medicare Advantage business is a key turnaround catalyst, but management’s commentary suggests the recovery is still being evaluated against changing healthcare costs and reimbursement conditions. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks
• Negative Sentiment: Investors remain concerned about 2027 pressure on Caremark from potential 340B program changes and declining membership. Those risks could offset current insurance improvements and help explain why the stock fell despite the earnings beat and higher 2026 outlook. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks

CVS Health Price Performance

NYSE CVS opened at $96.32 on Friday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The company has a fifty day simple moving average of $102.17 and a 200 day simple moving average of $87.68. The company has a market cap of $122.90 billion, a P/E ratio of 25.48, a P/E/G ratio of 0.90 and a beta of 0.61. CVS Health Corporation has a 1 year low of $62.55 and a 1 year high of $110.68.

CVS Health (NYSE:CVS) last posted its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.87 by $0.71. The business had revenue of $106.10 billion for the quarter, compared to analyst estimates of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health’s revenue was up 7.3% compared to the same quarter last year. During the same period last year, the business posted $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts predict that CVS Health Corporation will post 8 EPS for the current year.

CVS Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd were paid a $0.665 dividend. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.8%. CVS Health’s payout ratio is presently 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.